Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProFertil: Triptorelin for Fertility Protection in Young Women with Cancer
NCT05328258Phase 3Recruiting
- Start
- Mar 2023
- Primary completion
- Jan 2028
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Pamorelin in infertility. Primary endpoint: Anti-Müllerian Hormone levels in women with breast cancer. Started Mar 2023; status: recruiting.
02
Drugs
Pamorelin
03
Conditions
infertility
Beyond the preview
Go deeper on NCT05328258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328258.